ZMH - Zimmer Holdings, Inc. Common St

NYSE - NYSE Delayed Price. Currency in USD
0.00
0.00 (0.00%)
As of 4:07PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.00
Open0.00
Bid0.00 x 0
Ask0.00 x 0
Day's Range0.00 - 0.00
52 Week Range
Volume0
Avg. VolumeN/A
Market CapN/A
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Market Realist7 months ago

    Johnson & Johnson’s Medical Devices Segment

    Johnson & Johnson’s (JNJ) Medical Devices segment revenues decreased ~0.1% to ~$25.1 billion for 2016, compared to 2015.

  • PR Newswire10 months ago

    Zimmer Biomet Strengthens Spine Offering with PrimaGen Advanced™ Allograft

    WARSAW, Ind., Dec. 13, 2016 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today announced the launch of PrimaGen Advanced Allograft, an autograft substitute containing the same bone healing elements as autograft, but without the risks associated with donor site morbidity or harvest site complications.  Allograft is human tissue transplanted from a donor to a patient, while autograft tissue is transferred from one part of a patient's body to another.  PrimaGen Advanced Allograft offers a combination of demineralized cortical bone fibers with verified osteoinductivity and cancellous bone, providing a trabecular structure for natural bony in-growth with optimal handling and delivery characteristics. Dr. Donald Kucharzyk*, Orthopaedic Surgeon at The Orthopaedic, Pediatric and Spine Institute in Crown Point, Ind., was one of the first surgeons to use PrimaGen Advanced Allograft.  "The syringe allows for easy preparation and replication of the graft consistency prior to each use," noted Dr. Kucharzyk, who was pleased with the new delivery system, as well as the handling, moldability and stability under irrigation.

  • Market Realist10 months ago

    Johnson & Johnson’s Medical Devices Segment in 3Q16

    Johnson & Johnson’s (JNJ) Medical Devices segment grew ~1.1% to ~$6.2 billion for 3Q16 compared to 3Q15.

  • Reuters10 months ago

    Zimmer Biomet to settle bribery charges with U.S. prosecutors - filing

    U.S. authorities will reach a settlement with medical device maker Zimmer Biomet Holdings Inc over bribery allegations in the next four weeks, prosecutors said in a court filing Thursday. The new agreement would replace a 2012 settlement with the U.S. Justice Department over allegations that Biomet paid bribes to state-employed healthcare providers in Argentina, Brazil and China in order to win business. Prosecutors said in June that Biomet breached that agreement after the company came forward with new allegations of misconduct in Mexico and Brazil.

  • PR Newswire10 months ago

    Zimmer Biomet Announces the Early Tender Results and Upsizing of Its Cash Tender Offers for Certain Outstanding Debt Securities

    WARSAW, Ind., Dec. 5, 2016 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) (the "Company") today announced that, pursuant to its previously‑announced cash tender offers (the "Offers") for the debt securities identified in the table below (collectively, the "Notes"), approximately $2.6 billion in aggregate principal amount of Notes were validly tendered and not validly withdrawn on or prior to 5:00 p.m., New York City time, today, December 5, 2016 (the "Early Tender Deadline"). The Company also announced that it is increasing the aggregate purchase price (excluding accrued and unpaid interest to, but not including, the applicable settlement date and excluding fees related to the Offers) from $1.1 billion to $1.25 billion. The terms and conditions of the Offers are described in the Offer to Purchase dated November 21, 2016 (the "Offer to Purchase") and the related Letter of Transmittal (the "Letter of Transmittal"), and remain unchanged except as amended hereby.

  • Market Realistlast year

    JNJ’s Medical Devices Segment: How Did It Perform in 3Q16?

    Medical devices segment Johnson & Johnson’s (JNJ) Medical Devices segment grew ~1.1% to ~$6.2 billion between 3Q15 and 3Q16. This growth included an operational increase of 0.7% and a positive…